Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ: LGND )

105.03 -3.06 (-2.84%)
Streaming Delayed Price Updated: 12:37 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,840
Open 108.15
Bid (Size) 104.59 (1)
Ask (Size) 105.49 (3)
Prev. Close 108.09
Today's Range 103.48 - 109.27
52wk Range 67.72 - 129.90
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily

Performance

YTD
-3.13%
-3.13%
1 Month
-7.97%
-7.97%
3 Month
-12.74%
-12.74%
6 Month
+1.88%
+1.88%
1 Year
+45.14%
+45.14%

More News

Read More
Ligand to Present at Stifel 2024 Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
The Latest Analyst Ratings For Ligand Pharmaceuticals
Via Benzinga
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
Via Benzinga
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
From Palvella Therapeutics
Via GlobeNewswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Via Investor's Business Daily
Ligand Reports Second Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.